nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.12.2010 | NON-THEMATIC REVIEW

DNA methylation or histone modification status in metastasis and angiogenesis-related genes: a new hypothesis on usage of DNMT inhibitors and S-adenosylmethionine for genome stability

verfasst von: Mehmet Şahin, Emel Şahin, Saadet Gümüşlü, Abdullah Erdoğan, Meral Gültekin

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Metastasis is a leading cause of mortality and morbidity in cancer. This process needs angiogenesis. The biology underlying cancer, metastasis, and angiogenesis has been investigated so as to determine the therapeutic targets. Invasive and metastatic cancer cells have undergone numerous genetic and epigenetic changes, manifested by cytoskeletal changes, loss of adhesion, and expression of proteolytic enzymes that degrade the basement membrane. Additionally, in endothelial cells, some epigenetic modifications occur during the formation of angiogenesis. Researchers have used some methylation inhibitors, histone deacetylase inhibitors, or methylating agents (such as S-adenosylmethionine, SAM) against cancer and angiogenesis. Although they are effective to beat these diseases, each one results in differentiation or changes in genome structure. We review epigenetically modified genes related with angiogenesis and metastasis in cancer and endothelial cells, and suggest a new proposal. This hypothesis has discussed the importance of the usage of DNA methylation inhibitors together with SAM to prevent tumor progression and genome instability or changes resulting in additional diseases.

Mollabashy, A., & Scarborough, M. (2000). The mechanism of metastasis. The Orthopedic Clinics of North America, 31(4), 529–535.PubMed

Ehrlich, M. (2002). DNA methylation in cancer: Too much, but also too little. Oncogene, 21(35), 5400–5413.PubMed

Wolffe, A. P., & Matzke, M. A. (1999). Epigenetics: Regulation through repression. Science, 286(5439), 481–486.PubMed

Panning, B., & Jaenisch, R. (1998). RNA and the epigenetic regulation of X chromosome inactivation. Cell, 93(3), 305–308.PubMed

Li, E., Beard, C., & Jaenisch, R. (1993). Role for DNA methylation in genomic imprinting. Nature, 366(6453), 362–365.PubMed

Richardson, B. (2003). Impact of aging on DNA methylation. Ageing Research Reviews, 2(3), 245–261.PubMed

Sigalotti, L., Fratta, E., Coral, S., Cortini, E., Covre, A., Nicolay, H. J., et al. (2007). Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications. Journal of Cellular Physiology, 212(2), 330–344.PubMed

Hermann, A., Gowher, H., & Jeltsch, A. (2004). Biochemistry and biology of mammalian DNA methyltransferases. Cellular and Molecular Life Sciences, 61(19–20), 2571–2587.PubMed

Bussolino, F., Mantovani, A., & Persico, G. (1997). Molecular mechanisms of blood vessel formation. Trends in Biochemical Sciences, 22(7), 251–256.PubMed

10.

Esteller, M. (2005). DNA methylation and cancer therapy: New developments and expectations. Current Opinion in Oncology, 17(1), 55–60.PubMed

11.

Momparler, R. L., & Bovenzi, V. (2000). DNA methylation and cancer. Journal of Cellular Physiology, 183(2), 145–154.PubMed

12.

Razin, A., & Riggs, A. D. (1980). DNA methylation and gene function. Science, 210(4470), 604–610.PubMed

13.

Pulukuri, S. M., Estes, N., Patel, J., & Rao, J. S. (2007). Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Research, 67(3), 930–939.PubMed

14.

Hellebrekers, D. M., Jair, K. W., Vire, E., Eguchi, S., Hoebers, N. T., Fraga, M. F., et al. (2006). Angiostatic activity of DNA methyltransferase inhibitors. Molecular Cancer Therapeutics, 5(2), 467–475.PubMed

15.

Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J. E., Lee, S. W., et al. (2001). Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nature Medicine, 7(4), 437–443.PubMed

16.

Struhl, K. (1998). Histone acetylation and transcriptional regulatory mechanisms. Genes & Development, 12(5), 599–606.

17.

Noma, K., Allis, C. D., & Grewal, S. I. (2001). Transitions in distinct histone H3 methylation patterns at the heterochromatin domain boundaries. Science, 293(5532), 1150–1155.PubMed

18.

Nguyen, C. T., Weisenberger, D. J., Velicescu, M., Gonzales, F. A., Lin, J. C., Liang, G., et al. (2002). Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Research, 62(22), 6456–6461.PubMed

19.

Fahrner, J. A., Eguchi, S., Herman, J. G., & Baylin, S. B. (2002). Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Research, 62(24), 7213–7218.PubMed

20.

Hellebrekers, D. M., Melotte, V., Vire, E., Langenkamp, E., Molema, G., Fuks, F., et al. (2007). Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Research, 67(9), 4138–4148.PubMed

21.

Pedrazzani, C., Corso, G., Marrelli, D., & Roviello, F. (2007). E-cadherin and hereditary diffuse gastric cancer. Surgery, 142(5), 645–657.PubMed

22.

Perl, A. K., Wilgenbus, P., Dahl, U., Semb, H., & Christofori, G. (1998). A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature, 392(6672), 190–193.PubMed

23.

Qian, X., Karpova, T., Sheppard, A. M., McNally, J., & Lowy, D. R. (2004). E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. The EMBO Journal, 23(8), 1739–1748.PubMed

24.

Stockinger, A., Eger, A., Wolf, J., Beug, H., & Foisner, R. (2001). E-cadherin regulates cell growth by modulating proliferation-dependent beta-catenin transcriptional activity. The Journal of Cell Biology, 154(6), 1185–1196.PubMed

25.

Gottardi, C. J., Wong, E., & Gumbiner, B. M. (2001). E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. The Journal of Cell Biology, 153(5), 1049–1060.PubMed

26.

Wong, A. S., & Gumbiner, B. M. (2003). Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin. The Journal of Cell Biology, 161(6), 1191–1203.PubMed

27.

Bolos, V., Peinado, H., Perez-Moreno, M. A., Fraga, M. F., Esteller, M., & Cano, A. (2003). The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: A comparison with Snail and E47 repressors. Journal of Cell Science, 116(Pt 3), 499–511.PubMed

28.

Comijn, J., Berx, G., Vermassen, P., Verschueren, K., van Grunsven, L., Bruyneel, E., et al. (2001). The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Molecular Cell, 7(6), 1267–1278.PubMed

29.

De Craene, B., van Roy, F., & Berx, G. (2005). Unraveling signalling cascades for the Snail family of transcription factors. Cellular Signalling, 17(5), 535–547.PubMed

30.

Di Croce, L., & Pelicci, P. G. (2003). Tumour-associated hypermethylation: Silencing E-cadherin expression enhances invasion and metastasis. European Journal of Cancer, 39(4), 413–414.PubMed

31.

Wang, H. D., Ren, J., & Zhang, L. (2004). CDH1 germline mutation in hereditary gastric carcinoma. World Journal of Gastroenterology, 10(21), 3088–3093.PubMed

32.

Hirohashi, S. (1998). Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. The American Journal of Pathology, 153(2), 333–339.PubMed

33.

Graff, J. R., Gabrielson, E., Fujii, H., Baylin, S. B., & Herman, J. G. (2000). Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. The Journal of Biological Chemistry, 275(4), 2727–2732.PubMed

34.

Viswanathan, M., Tsuchida, N., & Shanmugam, G. (2003). Promoter hypermethylation profile of tumor-associated genes p16, p15, hMLH1, MGMT and E-cadherin in oral squamous cell carcinoma. International Journal of Cancer, 105(1), 41–46.

35.

de Moraes, R. V., Oliveira, D. T., Landman, G., de Carvalho, F., Caballero, O., Nonogaki, S., et al. (2008). E-cadherin abnormalities resulting from CPG methylation promoter in metastatic and nonmetastatic oral cancer. Head & Neck, 30(1), 85–92.

36.

Nass, S. J., Herman, J. G., Gabrielson, E., Iversen, P. W., Parl, F. F., Davidson, N. E., et al. (2000). Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. Cancer Research, 60(16), 4346–4348.PubMed

37.

Graff, J. R., Herman, J. G., Lapidus, R. G., Chopra, H., Xu, R., Jarrard, D. F., et al. (1995). E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Research, 55(22), 5195–5199.PubMed

38.

Mejlvang, J., Kriajevska, M., Berditchevski, F., Bronstein, I., Lukanidin, E. M., Pringle, J. H., et al. (2007). Characterization of E-cadherin-dependent and -independent events in a new model of c-Fos-mediated epithelial-mesenchymal transition. Experimental Cell Research, 313(2), 380–393.PubMed

39.

Kudo, Y., Kitajima, S., Ogawa, I., Hiraoka, M., Sargolzaei, S., Keikhaee, M. R., et al. (2004). Invasion and metastasis of oral cancer cells require methylation of E-cadherin and/or degradation of membranous beta-catenin. Clinical Cancer Research, 10(16), 5455–5463.PubMed

40.

Chang, H. W., Chow, V., Lam, K. Y., Wei, W. I., & Yuen, A. (2002). Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. Cancer, 94(2), 386–392.PubMed

41.

Nakayama, S., Sasaki, A., Mese, H., Alcalde, R. E., Tsuji, T., & Matsumura, T. (2001). The E-cadherin gene is silenced by CpG methylation in human oral squamous cell carcinomas. International Journal of Cancer, 93(5), 667–673.

42.

Yeh, K. T., Shih, M. C., Lin, T. H., Chen, J. C., Chang, J. Y., Kao, C. F., et al. (2002). The correlation between CpG methylation on promoter and protein expression of E-cadherin in oral squamous cell carcinoma. Anticancer Research, 22(6C), 3971–3975.PubMed

43.

Hasegawa, M., Nelson, H. H., Peters, E., Ringstrom, E., Posner, M., & Kelsey, K. T. (2002). Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene, 21(27), 4231–4236.PubMed

44.

Eggert, A., Ikegaki, N., Kwiatkowski, J., Zhao, H., Brodeur, G. M., & Himelstein, B. P. (2000). High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clinical Cancer Research, 6(5), 1900–1908.PubMed

45.

Hatzi, E., Murphy, C., Zoephel, A., Rasmussen, H., Morbidelli, L., Ahorn, H., et al. (2002). N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth. Oncogene, 21(22), 3552–3561.PubMed

46.

Adams, J. C. (2001). Thrombospondins: Multifunctional regulators of cell interactions. Annual Review of Cell and Developmental Biology, 17, 25–51.PubMed

47.

Bornstein, P. (1992). Thrombospondins: Structure and regulation of expression. The FASEB Journal, 6(14), 3290–3299.PubMed

48.

Jimenez, B., Volpert, O. V., Crawford, S. E., Febbraio, M., Silverstein, R. L., & Bouck, N. (2000). Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nature Medicine, 6(1), 41–48.PubMed

49.

Tolsma, S. S., Volpert, O. V., Good, D. J., Frazier, W. A., Polverini, P. J., & Bouck, N. (1993). Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. The Journal of Cell Biology, 122(2), 497–511.PubMed

50.

Suzuma, K., Takagi, H., Otani, A., Oh, H., & Honda, Y. (1999). Expression of thrombospondin-1 in ischemia-induced retinal neovascularization. The American Journal of Pathology, 154(2), 343–354.PubMed

51.

Sheibani, N., & Frazier, W. A. (1995). Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 92(15), 6788–6792.PubMed

52.

Weinstat-Saslow, D. L., Zabrenetzky, V. S., VanHoutte, K., Frazier, W. A., Roberts, D. D., & Steeg, P. S. (1994). Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Research, 54(24), 6504–6511.PubMed

53.

Zabrenetzky, V., Harris, C. C., Steeg, P. S., & Roberts, D. D. (1994). Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. International Journal of Cancer, 59(2), 191–195.

54.

Lawler, J. (2002). Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. Journal of Cellular and Molecular Medicine, 6(1), 1–12.PubMed

55.

Gilmore, A. P., & Romer, L. H. (1996). Inhibition of focal adhesion kinase (FAK) signaling in focal adhesions decreases cell motility and proliferation. Molecular Biology of the Cell, 7(8), 1209–1224.PubMed

56.

Dameron, K. M., Volpert, O. V., Tainsky, M. A., & Bouck, N. (1994). Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science, 265(5178), 1582–1584.PubMed

57.

Yang, Q. W., Liu, S., Tian, Y., Salwen, H. R., Chlenski, A., Weinstein, J., et al. (2003). Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Research, 63(19), 6299–6310.PubMed

58.

Miyamoto, N., Yamamoto, H., Taniguchi, H., Miyamoto, C., Oki, M., Adachi, Y., et al. (2007). Differential expression of angiogenesis-related genes in human gastric cancers with and those without high-frequency microsatellite instability. Cancer Letters, 254(1), 42–53.PubMed

59.

Kanai, Y., Ushijima, S., Kondo, Y., Nakanishi, Y., & Hirohashi, S. (2001). DNA methyltransferase expression and DNA methylation of CPG islands and peri-centromeric satellite regions in human colorectal and stomach cancers. International Journal of Cancer, 91(2), 205–212.

60.

Ueki, T., Toyota, M., Sohn, T., Yeo, C. J., Issa, J. P., Hruban, R. H., et al. (2000). Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Research, 60(7), 1835–1839.PubMed

61.

Hu, C. J., Chen, S. D., Yang, D. I., Lin, T. N., Chen, C. M., Huang, T. H., et al. (2006). Promoter region methylation and reduced expression of thrombospondin-1 after oxygen-glucose deprivation in murine cerebral endothelial cells. Journal of Cerebral Blood Flow and Metabolism, 26(12), 1519–1526.PubMed

62.

Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G., & Baylin, S. B. (1999). Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genetics, 21(1), 103–107.PubMed

63.

Anand-Apte, B., Bao, L., Smith, R., Iwata, K., Olsen, B. R., Zetter, B., et al. (1996). A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochemistry and Cell Biology, 74(6), 853–862.PubMed

64.

Ahonen, M., Baker, A. H., & Kahari, V. M. (1998). Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Research, 58(11), 2310–2315.PubMed

65.

Qi, J. H., Ebrahem, Q., Moore, N., Murphy, G., Claesson-Welsh, L., Bond, M., et al. (2003). A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): İnhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nature Medicine, 9(4), 407–415.PubMed

66.

Fendrich, V., Slater, E. P., Heinmoller, E., Ramaswamy, A., Celik, I., Nowak, O., et al. (2005). Alterations of the tissue inhibitor of metalloproteinase-3 (TIMP3) gene in pancreatic adenocarcinomas. Pancreas, 30(2), e40–e45.PubMed

67.

Bachman, K. E., Herman, J. G., Corn, P. G., Merlo, A., Costello, J. F., Cavenee, W. K., et al. (1999). Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Research, 59(4), 798–802.PubMed

68.

Wild, A., Ramaswamy, A., Langer, P., Celik, I., Fendrich, V., Chaloupka, B., et al. (2003). Frequent methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene in pancreatic endocrine tumors. The Journal of Clinical Endocrinology and Metabolism, 88(3), 1367–1373.PubMed

69.

Lee, S., Kim, W. H., Jung, H. Y., Yang, M. H., & Kang, G. H. (2002). Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. The American Journal of Pathology, 161(3), 1015–1022.PubMed

70.

Lui, E. L., Loo, W. T., Zhu, L., Cheung, M. N., & Chow, L. W. (2005). DNA hypermethylation of TIMP3 gene in invasive breast ductal carcinoma. Biomedicine & Pharmacotherapy, 59(Suppl 2), S363–S365.

71.

van der Velden, P. A., Zuidervaart, W., Hurks, M. H., Pavey, S., Ksander, B. R., Krijgsman, E., et al. (2003). Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development. International Journal of Cancer, 106(4), 472–479.

72.

Mooy, C. M., & De Jong, P. T. (1996). Prognostic parameters in uveal melanoma: A review. Survey of Ophthalmology, 41(3), 215–228.PubMed

73.

Kim, Y. H., Petko, Z., Dzieciatkowski, S., Lin, L., Ghiassi, M., Stain, S., et al. (2006). CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer. Genes, Chromosomes & Cancer, 45(8), 781–789.

74.

Ebert, M. P., Mooney, S. H., Tonnes-Priddy, L., Lograsso, J., Hoffmann, J., Chen, J., et al. (2005). Hypermethylation of the TPEF/HPP1 gene in primary and metastatic colorectal cancers. Neoplasia, 7(8), 771–778.PubMed

75.

Harris, A. L. (2002). Hypoxia—A key regulatory factor in tumour growth. Nature Reviews, 2(1), 38–47.PubMed

76.

Ohh, M. (2006). Ubiquitin pathway in VHL cancer syndrome. Neoplasia, 8(8), 623–629.PubMed

77.

Pugh, C. W., & Ratcliffe, P. J. (2003). Regulation of angiogenesis by hypoxia: Role of the HIF system. Nature Medicine, 9(6), 677–684.PubMed

78.

Kim, W. Y., & Kaelin, W. G. (2004). Role of VHL gene mutation in human cancer. Journal of Clinical Oncology, 22(24), 4991–5004.PubMed

79.

Russell, R. C., & Ohh, M. (2007). The role of VHL in the regulation of E-cadherin: A new connection in an old pathway. Cell Cycle, 6(1), 56–59.PubMed

80.

Knudson, A. G., Jr. (1979). Hereditary cancer. JAMA, 241(3), 279.PubMed

81.

Thelen, P., Hemmerlein, B., Kugler, A., Seiler, T., Ozisik, R., Kallerhoff, M., et al. (1999). Quantification by competitive quantitative RT-PCR of VEGF121 and VEGF165 in renal cell carcinoma. Anticancer Research, 19(2C), 1563–1565.PubMed

82.

Banks, R. E., Tirukonda, P., Taylor, C., Hornigold, N., Astuti, D., Cohen, D., et al. (2006). Genetic and epigenetic analysis of von Hippel–Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Research, 66(4), 2000–2011.PubMed

83.

Kim, J. H., Jung, C. W., Cho, Y. H., Lee, J., Lee, S. H., Kim, H. Y., et al. (2005). Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncology Reports, 13(5), 859–864.PubMed

84.

Rini, B. I., Jaeger, E., Weinberg, V., Sein, N., Chew, K., Fong, K., et al. (2006). Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: İmpact of patient characteristics and Von Hippel–Lindau gene status. BJU International, 98(4), 756–762.PubMed

85.

Lassaletta, L., Bello, M. J., Del Rio, L., Alfonso, C., Roda, J. M., Rey, J. A., et al. (2006). DNA methylation of multiple genes in vestibular schwannoma: Relationship with clinical and radiological findings. Otology & Neurotology, 27(8), 1180–1185.

86.

Cao, Z., Song, J. H., Kim, C. J., Cho, Y. G., Kim, S. Y., Nam, S. W., et al. (2008). Genetic and epigenetic analysis of the VHL gene in gastric cancers. Acta Oncológica, 47(8), 1551–1556.PubMed

87.

Xu, X. L., Yu, J., Zhang, H. Y., Sun, M. H., Gu, J., Du, X., et al. (2004). Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World Journal of Gastroenterology, 10(23), 3441–3454.PubMed

88.

Van Lint, J., Rykx, A., Maeda, Y., Vantus, T., Sturany, S., Malhotra, V., et al. (2002). Protein kinase D: An intracellular traffic regulator on the move. Trends in Cell Biology, 12(4), 193–200.PubMed

89.

Rozengurt, E., Rey, O., & Waldron, R. T. (2005). Protein kinase D signaling. The Journal of Biological Chemistry, 280(14), 13205–13208.PubMed

90.

Kim, M., Jang, H. R., Kim, J. H., Noh, S. M., Song, K. S., Cho, J. S., et al. (2008). Epigenetic inactivation of protein kinase D1 in gastric cancer and its role in gastric cancer cell migration and invasion. Carcinogenesis, 29(3), 629–637.PubMed

91.

Jaggi, M., Rao, P. S., Smith, D. J., Wheelock, M. J., Johnson, K. R., Hemstreet, G. P., et al. (2005). E-cadherin phosphorylation by protein kinase D1/protein kinase C{mu} is associated with altered cellular aggregation and motility in prostate cancer. Cancer Research, 65(2), 483–492.PubMed

92.

Sjoblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., et al. (2006). The consensus coding sequences of human breast and colorectal cancers. Science, 314, 268–274.PubMed

93.

Jaggi, M., Rao, P. S., Smith, D. J., Hemstreet, G. P., & Balaji, K. C. (2003). Protein kinase C mu is down-regulated in androgen-independent prostate cancer. Biochemical and Biophysical Research Communications, 307(2), 254–260.PubMed

94.

Zou, Z., Anisowicz, A., Hendrix, M. J., Thor, A., Neveu, M., Sheng, S., et al. (1994). Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science, 263(5146), 526–529.PubMed

95.

Futscher, B. W., Oshiro, M. M., Wozniak, R. J., Holtan, N., Hanigan, C. L., Duan, H., et al. (2002). Role for DNA methylation in the control of cell type specific maspin expression. Nature Genetics, 31(2), 175–179.PubMed

96.

Sheng, S., Carey, J., Seftor, E. A., Dias, L., Hendrix, M. J., & Sager, R. (1996). Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 93(21), 11669–11674.PubMed

97.

Xia, W., Lau, Y. K., Hu, M. C., Li, L., Johnston, D. A., Sheng, S., et al. (2000). High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. Oncogene, 19(20), 2398–2403.PubMed

98.

Maass, N., Hojo, T., Rosel, F., Ikeda, T., Jonat, W., & Nagasaki, K. (2001). Down regulation of the tumor suppressor gene maspin in breast carcinoma is associated with a higher risk of distant metastasis. Clinical Biochemistry, 34(4), 303–307.PubMed

99.

Maass, N., Teffner, M., Rosel, F., Pawaresch, R., Jonat, W., Nagasaki, K., et al. (2001). Decline in the expression of the serine proteinase inhibitor maspin is associated with tumour progression in ductal carcinomas of the breast. The Journal of Pathology, 195(3), 321–326.PubMed

100.

Shi, H. Y., Zhang, W., Liang, R., Abraham, S., Kittrell, F. S., Medina, D., et al. (2001). Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model. Cancer Research, 61(18), 6945–6951.PubMed

101.

Seftor, R. E., Seftor, E. A., Sheng, S., Pemberton, P. A., Sager, R., & Hendrix, M. J. (1998). Maspin suppresses the invasive phenotype of human breast carcinoma. Cancer Research, 58(24), 5681–5685.PubMed

102.

Maass, N., Hojo, T., Ueding, M., Luttges, J., Kloppel, G., Jonat, W., et al. (2001). Expression of the tumor suppressor gene Maspin in human pancreatic cancers. Clinical Cancer Research, 7(4), 812–817.PubMed

103.

Sood, A. K., Fletcher, M. S., Gruman, L. M., Coffin, J. E., Jabbari, S., Khalkhali-Ellis, Z., et al. (2002). The paradoxical expression of maspin in ovarian carcinoma. Clinical Cancer Research, 8(9), 2924–2932.PubMed

104.

Ogasawara, S., Maesawa, C., Yamamoto, M., Akiyama, Y., Wada, K., Fujisawa, K., et al. (2004). Disruption of cell-type-specific methylation at the Maspin gene promoter is frequently involved in undifferentiated thyroid cancers. Oncogene, 23(5), 1117–1124.PubMed

105.

Zhang, M., Volpert, O., Shi, Y. H., & Bouck, N. (2000). Maspin is an angiogenesis inhibitor. Nature Medicine, 6(2), 196–199.PubMed

106.

Zhang, M., Maass, N., Magit, D., & Sager, R. (1997). Transactivation through Ets and Ap1 transcription sites determines the expression of the tumor-suppressing gene maspin. Cell Growth & Differentiation, 8(2), 179–186.

107.

Domann, F. E., Rice, J. C., Hendrix, M. J., & Futscher, B. W. (2000). Epigenetic silencing of maspin gene expression in human breast cancers. International Journal of Cancer, 85(6), 805–810.

108.

Murakami, J., Asaumi, J., Maki, Y., Tsujigiwa, H., Kuroda, M., Nagai, N., et al. (2004). Effects of demethylating agent 5-aza-2(')-deoxycytidine and histone deacetylase inhibitor FR901228 on maspin gene expression in oral cancer cell lines. Oral Oncology, 40(6), 597–603.PubMed

109.

Akiyama, Y., Maesawa, C., Ogasawara, S., Terashima, M., & Masuda, T. (2003). Cell-type-specific repression of the maspin gene is disrupted frequently by demethylation at the promoter region in gastric intestinal metaplasia and cancer cells. The American Journal of Pathology, 163(5), 1911–1919.PubMed

110.

Terashima, M., Maesawa, C., Oyama, K., Ohtani, S., Akiyama, Y., Ogasawara, S., et al. (2005). Gene expression profiles in human gastric cancer: Expression of maspin correlates with lymph node metastasis. British Journal of Cancer, 92(6), 1130–1136.PubMed

111.

Wada, K., Maesawa, C., Akasaka, T., & Masuda, T. (2004). Aberrant expression of the maspin gene associated with epigenetic modification in melanoma cells. The Journal of Investigative Dermatology, 122(3), 805–811.PubMed

112.

Noda, M., Kitayama, H., Matsuzaki, T., Sugimoto, Y., Okayama, H., Bassin, R. H., et al. (1989). Detection of genes with a potential for suppressing the transformed phenotype associated with activated ras genes. Proceedings of the National Academy of Sciences of the United States of America, 86(1), 162–166.PubMed

113.

Takahashi, C., Sheng, Z., Horan, T. P., Kitayama, H., Maki, M., Hitomi, K., et al. (1998). Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proceedings of the National Academy of Sciences of the United States of America, 95(22), 13221–13226.PubMed

114.

Oh, J., Takahashi, R., Kondo, S., Mizoguchi, A., Adachi, E., Sasahara, R. M., et al. (2001). The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell, 107(6), 789–800.PubMed

115.

Masui, T., Doi, R., Koshiba, T., Fujimoto, K., Tsuji, S., Nakajima, S., et al. (2003). RECK expression in pancreatic cancer: İts correlation with lower invasiveness and better prognosis. Clinical Cancer Research, 9(5), 1779–1784.PubMed

116.

Span, P. N., Sweep, C. G., Manders, P., Beex, L. V., Leppert, D., & Lindberg, R. L. (2003). Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: A prognostic marker for good clinical outcome in human breast carcinoma. Cancer, 97(11), 2710–2715.PubMed

117.

Takenaka, K., Ishikawa, S., Kawano, Y., Yanagihara, K., Miyahara, R., Otake, Y., et al. (2004). Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer. European Journal of Cancer, 40(10), 1617–1623.PubMed

118.

Takeuchi, T., Hisanaga, M., Nagao, M., Ikeda, N., Fujii, H., Koyama, F., et al. (2004). The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clinical Cancer Research, 10(16), 5572–5579.PubMed

119.

Takenaka, K., Ishikawa, S., Yanagihara, K., Miyahara, R., Hasegawa, S., Otake, Y., et al. (2005). Prognostic significance of reversion-inducing cysteine-rich protein with Kazal motifs expression in resected pathologic stage IIIA N2 non-small-cell lung cancer. Annals of Surgical Oncology, 12(10), 817–824.PubMed

120.

van der Jagt, M. F., Sweep, F. C., Waas, E. T., Hendriks, T., Ruers, T. J., Merry, A. H., et al. (2006). Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer. Cancer Letters, 237(2), 289–297.PubMed

121.

Cho, C. Y., Wang, J. H., Chang, H. C., Chang, C. K., & Hung, W. C. (2007). Epigenetic inactivation of the metastasis suppressor RECK enhances invasion of human colon cancer cells. Journal of Cellular Physiology, 213(1), 65–69.PubMed

122.

Chang, H. C., Cho, C. Y., & Hung, W. C. (2007). Downregulation of RECK by promoter methylation correlates with lymph node metastasis in non-small cell lung cancer. Cancer Science, 98(2), 169–173.PubMed

123.

Ichikawa, T., Kyprianou, N., & Isaacs, J. T. (1990). Genetic instability and the acquisition of metastatic ability by rat mammary cancer cells following v-H-ras oncogene transfection. Cancer Research, 50(19), 6349–6357.PubMed

124.

Chang, H. C., Liu, L. T., & Hung, W. C. (2004). Involvement of histone deacetylation in ras-induced down-regulation of the metastasis suppressor RECK. Cellular Signalling, 16(6), 675–679.PubMed

125.

Chang, H. C., Cho, C. Y., & Hung, W. C. (2006). Silencing of the metastasis suppressor RECK by RAS oncogene is mediated by DNA methyltransferase 3b-induced promoter methylation. Cancer Research, 66(17), 8413–8420.PubMed

126.

Van Veldhuizen, P. J., Sadasivan, R., Cherian, R., & Wyatt, A. (1996). Urokinase-type plasminogen activator expression in human prostate carcinomas. The American Journal of the Medical Sciences, 312(1), 8–11.PubMed

127.

Lakka, S. S., Bhattacharya, A., Mohanam, S., Boyd, D., & Rao, J. S. (2001). Regulation of the uPA gene in various grades of human glioma cells. International Journal of Oncology, 18(1), 71–79.PubMed

128.

Look, M. P., & Foekens, J. A. (1999). Clinical relevance of the urokinase plasminogen activator system in breast cancer. APMIS, 107(1), 150–159.PubMed

129.

Pyke, C., Kristensen, P., Ralfkiaer, E., Grondahl-Hansen, J., Eriksen, J., Blasi, F., et al. (1991). Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. The American Journal of Pathology, 138(5), 1059–1067.PubMed

130.

Skriver, L., Larsson, L. I., Kielberg, V., Nielsen, L. S., Andresen, P. B., Kristensen, P., et al. (1984). Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. The Journal of Cell Biology, 99(2), 753–757.PubMed

131.

Rabbani, S. A., & Mazar, A. P. (2001). The role of the plasminogen activation system in angiogenesis and metastasis. Surgical Oncology Clinics of North America, 10(2), 393–415. x.PubMed

132.

Stewart, D. A., Cooper, C. R., & Sikes, R. A. (2004). Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer. Reproductive Biology and Endocrinology, 2, 2.PubMed

133.

Aguirre-Ghiso, J. A., Estrada, Y., Liu, D., & Ossowski, L. (2003). ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Research, 63(7), 1684–1695.PubMed

134.

Hsu, D. W., Efird, J. T., & Hedley-Whyte, E. T. (1995). Prognostic role of urokinase-type plasminogen activator in human gliomas. The American Journal of Pathology, 147(1), 114–123.PubMed

135.

Miyake, H., Hara, I., Yamanaka, K., Arakawa, S., & Kamidono, S. (1999). Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. International Journal of Oncology, 14(3), 535–541.PubMed

136.

Schweinitz, A., Steinmetzer, T., Banke, I. J., Arlt, M. J., Sturzebecher, A., Schuster, O., et al. (2004). Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. The Journal of Biological Chemistry, 279(32), 33613–33622.PubMed

137.

Pulukuri, S. M., Gondi, C. S., Lakka, S. S., Jutla, A., Estes, N., Gujrati, M., et al. (2005). RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. The Journal of Biological Chemistry, 280(43), 36529–36540.PubMed

138.

Gondi, C. S., Lakka, S. S., Yanamandra, N., Siddique, K., Dinh, D. H., Olivero, W. C., et al. (2003). Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene, 22(38), 5967–5975.PubMed

139.

Pakneshan, P., Tetu, B., & Rabbani, S. A. (2004). Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma. Clinical Cancer Research, 10(9), 3035–3041.PubMed

140.

Guo, Y., Pakneshan, P., Gladu, J., Slack, A., Szyf, M., & Rabbani, S. A. (2002). Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion. The Journal of Biological Chemistry, 277(44), 41571–41579.PubMed

141.

Pakneshan, P., Xing, R. H., & Rabbani, S. A. (2003). Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo. The FASEB Journal, 17(9), 1081–1088.PubMed

142.

Detich, N., Hamm, S., Just, G., Knox, J. D., & Szyf, M. (2003). The methyl donor S-adenosylmethionine inhibits active demethylation of DNA: A candidate novel mechanism for the pharmacological effects of S-adenosylmethionine. The Journal of Biological Chemistry, 278(23), 20812–20820.PubMed

143.

Pakneshan, P., Szyf, M., Farias-Eisner, R., & Rabbani, S. A. (2004). Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. The Journal of Biological Chemistry, 279(30), 31735–31744.PubMed

144.

Slack, A., Bovenzi, V., Bigey, P., Ivanov, M. A., Ramchandani, S., Bhattacharya, S., et al. (2002). Antisense MBD2 gene therapy inhibits tumorigenesis. The Journal of Gene Medicine, 4(4), 381–389.PubMed

145.

Sansom, O. J., Berger, J., Bishop, S. M., Hendrich, B., Bird, A., & Clarke, A. R. (2003). Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nature Genetics, 34(2), 145–147.PubMed

146.

Shukeir, N., Pakneshan, P., Chen, G., Szyf, M., & Rabbani, S. A. (2006). Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. Cancer Research, 66(18), 9202–9210.PubMed

147.

Brehmer, B., Biesterfeld, S., & Jakse, G. (2003). Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. Prostate Cancer and Prostatic Diseases, 6(3), 217–222.PubMed

148.

Ogishima, T., Shiina, H., Breault, J. E., Tabatabai, L., Bassett, W. W., Enokida, H., et al. (2005). Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clinical Cancer Research, 11(3), 1028–1036.PubMed

149.

Tokizane, T., Shiina, H., Igawa, M., Enokida, H., Urakami, S., Kawakami, T., et al. (2005). Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clinical Cancer Research, 11(16), 5793–5801.PubMed

150.

Liu, H., Liu, W., Wu, Y., Zhou, Y., Xue, R., Luo, C., et al. (2005). Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers. Cancer Research, 65(17), 7635–7643.PubMed

151.

Paredes, J., Albergaria, A., Oliveira, J. T., Jeronimo, C., Milanezi, F., & Schmitt, F. C. (2005). P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clinical Cancer Research, 11(16), 5869–5877.PubMed

152.

Nishigaki, M., Aoyagi, K., Danjoh, I., Fukaya, M., Yanagihara, K., Sakamoto, H., et al. (2005). Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays. Cancer Research, 65(6), 2115–2124.PubMed

153.

Szyf, M. (2005). DNA methylation and demethylation as targets for anticancer therapy. Biochemistry, 70(5), 533–549.PubMed

154.

Carmeliet, P. (2005). Angiogenesis in life, disease and medicine. Nature, 438(7070), 932–936.PubMed

155.

Deroanne, C. F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., et al. (2002). Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene, 21(3), 427–436.PubMed

156.

Boehm, T., Folkman, J., Browder, T., & O’Reilly, M. S. (1997). Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 390(6658), 404–407.PubMed

157.

Sahin, M., Sahin, E., & Gumuslu, S. (2009). Cyclooxygenase-2 in cancer and angiogenesis. Angiology, 60(2), 242–253.PubMed

158.

Qian, D. Z., Wang, X., Kachhap, S. K., Kato, Y., Wei, Y., Zhang, L., et al. (2004). The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Research, 64(18), 6626–6634.PubMed

159.

Miao, H. Q., Soker, S., Feiner, L., Alonso, J. L., Raper, J. A., & Klagsbrun, M. (1999). Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: Functional competition of collapsin-1 and vascular endothelial growth factor-165. The Journal of Cell Biology, 146(1), 233–242.PubMed

160.

Ignarro, L. J., Buga, G. M., Wood, K. S., Byrns, R. E., & Chaudhuri, G. (1987). Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proceedings of the National Academy of Sciences of the United States of America, 84(24), 9265–9269.PubMed

161.

Murohara, T., Asahara, T., Silver, M., Bauters, C., Masuda, H., Kalka, C., et al. (1998). Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. The Journal of Clinical Investigation, 101(11), 2567–2578.PubMed

162.

Duplain, H., Burcelin, R., Sartori, C., Cook, S., Egli, M., Lepori, M., et al. (2001). Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation, 104(3), 342–345.PubMed

163.

Rossig, L., Li, H., Fisslthaler, B., Urbich, C., Fleming, I., Forstermann, U., et al. (2002). Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circulation Research, 91(9), 837–844.PubMed

164.

Altieri, D. C. (2003). Validating survivin as a cancer therapeutic target. Nature Reviews, 3(1), 46–54.PubMed

165.

Holash, J., Wiegand, S. J., & Yancopoulos, G. D. (1999). New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene, 18(38), 5356–5362.PubMed

166.

Gartel, A. L., & Radhakrishnan, S. K. (2005). Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Research, 65(10), 3980–3985.PubMed

167.

Garner, E., & Raj, K. (2008). Protective mechanisms of p53-p21-pRb proteins against DNA damage-induced cell death. Cell Cycle, 7(3), 277–282.PubMed

168.

Hellebrekers, D. M., Castermans, K., Vire, E., Dings, R. P., Hoebers, N. T., Mayo, K. H., et al. (2006). Epigenetic regulation of tumor endothelial cell anergy: Silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Research, 66(22), 10770–10777.PubMed

169.

Friedrich, M. G., Chandrasoma, S., Siegmund, K. D., Weisenberger, D. J., Cheng, J. C., Toma, M. I., et al. (2005). Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. European Journal of Cancer, 41(17), 2769–2778.PubMed

170.

Fuks, F., Burgers, W. A., Brehm, A., Hughes-Davies, L., & Kouzarides, T. (2000). DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nature Genetics, 24(1), 88–91.PubMed

171.

Robertson, K. D., Ait-Si-Ali, S., Yokochi, T., Wade, P. A., Jones, P. L., & Wolffe, A. P. (2000). DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nature Genetics, 25(3), 338–342.PubMed

172.

Franklin, S. L., Ferry, R. J., Jr., & Cohen, P. (2003). Rapid insulin-like growth factor (IGF)-independent effects of IGF binding protein-3 on endothelial cell survival. The Journal of Clinical Endocrinology and Metabolism, 88(2), 900–907.PubMed

173.

Iwatsuki, K., Tanaka, K., Kaneko, T., Kazama, R., Okamoto, S., Nakayama, Y., et al. (2005). Runx1 promotes angiogenesis by downregulation of insulin-like growth factor-binding protein-3. Oncogene, 24(7), 1129–1137.PubMed

174.

Chang, Y. S., Wang, L., Liu, D., Mao, L., Hong, W. K., Khuri, F. R., et al. (2002). Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clinical Cancer Research, 8(12), 3669–3675.PubMed

175.

Bocci, G., Francia, G., Man, S., Lawler, J., & Kerbel, R. S. (2003). Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 100(22), 12917–12922.PubMed

176.

Passegue, E., & Wagner, E. F. (2000). JunB suppresses cell proliferation by transcriptional activation of p16(INK4a) expression. The EMBO Journal, 19(12), 2969–2979.PubMed

177.

Li, Q., Ahuja, N., Burger, P. C., & Issa, J. P. (1999). Methylation and silencing of the thrombospondin-1 promoter in human cancer. Oncogene, 18(21), 3284–3289.PubMed

178.

Yang, M. Y., Liu, T. C., Chang, J. G., Lin, P. M., & Lin, S. F. (2003). JunB gene expression is inactivated by methylation in chronic myeloid leukemia. Blood, 101(8), 3205–3211.PubMed

179.

Chen, T., Turner, J., McCarthy, S., Scaltriti, M., Bettuzzi, S., & Yeatman, T. J. (2004). Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent. Cancer Research, 64(20), 7412–7419.PubMed

180.

Zhang, H., Kim, J. K., Edwards, C. A., Xu, Z., Taichman, R., & Wang, C. Y. (2005). Clusterin inhibits apoptosis by interacting with activated Bax. Nature Cell Biology, 7(9), 909–915.PubMed

181.

Jackson, J. K., Gleave, M. E., Gleave, J., & Burt, H. M. (2005). The inhibition of angiogenesis by antisense oligonucleotides to clusterin. Angiogenesis, 8(3), 229–238.PubMed

182.

Sivamurthy, N., Stone, D. H., LoGerfo, F. W., & Quist, W. C. (2001). Apolipoprotein J inhibits the migration and adhesion of endothelial cells. Surgery, 130(2), 204–209.PubMed

183.

Leskov, K. S., Klokov, D. Y., Li, J., Kinsella, T. J., & Boothman, D. A. (2003). Synthesis and functional analyses of nuclear clusterin, a cell death protein. The Journal of Biological Chemistry, 278(13), 11590–11600.PubMed

184.

Handford, P. A. (2000). Fibrillin-1, a calcium binding protein of extracellular matrix. Biochimica et Biophysica Acta, 1498(2–3), 84–90.PubMed

185.

Carta, L., Pereira, L., Arteaga-Solis, E., Lee-Arteaga, S. Y., Lenart, B., Starcher, B., et al. (2006). Fibrillins 1 and 2 perform partially overlapping functions during aortic development. The Journal of Biological Chemistry, 281(12), 8016–8023.PubMed

186.

Wilson, D. G., Bellamy, M. F., Ramsey, M. W., Goodfellow, J., Brownlee, M., Davies, S., et al. (1999). Endothelial function in Marfan syndrome: Selective impairment of flow-mediated vasodilation. Circulation, 99(7), 909–915.PubMed

187.

Coppock, D. L., Cina-Poppe, D., & Gilleran, S. (1998). The quiescin Q6 gene (QSCN6) is a fusion of two ancient gene families: Thioredoxin and ERV1. Genomics, 54(3), 460–468.PubMed

188.

Chiba, T., Yokosuka, O., Fukai, K., Kojima, H., Tada, M., Arai, M., et al. (2004). Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells. Oncology, 66(6), 481–491.PubMed

189.

Lund, P., Weisshaupt, K., Mikeska, T., Jammas, D., Chen, X., Kuban, R. J., et al. (2006). Oncogenic HRAS suppresses clusterin expression through promoter hypermethylation. Oncogene, 25(35), 4890–4903.PubMed

190.

Lehnertz, B., Ueda, Y., Derijck, A. A., Braunschweig, U., Perez-Burgos, L., Kubicek, S., et al. (2003). Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin. Current Biology, 13(14), 1192–1200.PubMed

191.

Rountree, M. R., Bachman, K. E., & Baylin, S. B. (2000). DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nature Genetics, 25(3), 269–277.PubMed

192.

Feinberg, A. P., & Vogelstein, B. (1983). Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature, 301(5895), 89–92.PubMed

193.

Chen, R. Z., Pettersson, U., Beard, C., Jackson-Grusby, L., & Jaenisch, R. (1998). DNA hypomethylation leads to elevated mutation rates. Nature, 395(6697), 89–93.PubMed

194.

Bachman, K. E., Park, B. H., Rhee, I., Rajagopalan, H., Herman, J. G., Baylin, S. B., et al. (2003). Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell, 3(1), 89–95.PubMed

195.

Butler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon-Cardo, C., et al. (2000). Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Research, 60(18), 5165–5170.PubMed

196.

Saaristo, A., Karpanen, T., & Alitalo, K. (2000). Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene, 19(53), 6122–6129.PubMed

197.

Grady, W. M. (2005). Epigenetic events in the colorectum and in colon cancer. Biochemical Society Transactions, 33(Pt 4), 684–688.PubMed

198.

Baylin, S. B., Esteller, M., Rountree, M. R., Bachman, K. E., Schuebel, K., & Herman, J. G. (2001). Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Human Molecular Genetics, 10(7), 687–692.PubMed

199.

Baylin, S. B., & Ohm, J. E. (2006). Epigenetic gene silencing in cancer—A mechanism for early oncogenic pathway addiction? Nature Reviews, 6(2), 107–116.PubMed

200.

Maier, S., Dahlstroem, C., Haefliger, C., Plum, A., & Piepenbrock, C. (2005). Identifying DNA methylation biomarkers of cancer drug response. American Journal of Pharmacogenomics, 5(4), 223–232.PubMed

201.

Weiser, T. S., Guo, Z. S., Ohnmacht, G. A., Parkhurst, M. L., Tong-On, P., Marincola, F. M., et al. (2001). Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. Journal of Immunotherapy, 24(2), 151–161.PubMed

202.

Gagnon, J., Shaker, S., Primeau, M., Hurtubise, A., & Momparler, R. L. (2003). Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells. Anti-Cancer Drugs, 14(3), 193–202.PubMed

Titel: DNA methylation or histone modification status in metastasis and angiogenesis-related genes: a new hypothesis on usage of DNMT inhibitors and S-adenosylmethionine for genome stability
verfasst von: Mehmet Şahin
Emel Şahin
Saadet Gümüşlü
Abdullah Erdoğan
Meral Gültekin
Publikationsdatum: 01.12.2010
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 4/2010
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-010-9253-0

Springer Medizin

DNA methylation or histone modification status in metastasis and angiogenesis-related genes: a new hypothesis on usage of DNMT inhibitors and S-adenosylmethionine for genome stability

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2010

Stem cell marker olfactomedin 4: critical appraisal of its characteristics and role in tumorigenesis

Distant metastases do not metastasize

Cytochrome P450-derived eicosanoids: the neglected pathway in cancer

Erratum to: microRNAs and lung cancer: tumors and 22-mers

Malignant melanoma as a target malignancy for the study of the anti-metastatic properties of the heparins

CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie